Skip to main navigation
Nektar Therapeutics
  • About Nektar
    • Our Story
    • Leadership
    • Partnering for Innovation
    • Contact Us
  • Our Pipeline
    • Pipeline
    • Clinical Trials
  • Our Science
    • Scientific Approach
    • Scientific Publications
  • Investors
    • Investor Overview
    • Financials & Filings
    • Press Releases
    • SEC Filings
    • Investor Events
    • Corporate Governance
    • Stock Information
    • Contact IR
    • Historic Stock Lookup
    • Email Alerts
    • Analyst Coverage
  • Our Culture
    • Careers at Nektar
  • For Patients
  • linkedin
Nektar Therapeutics
  • About Nektar
    • Our Story
    • Leadership
    • Partnering for Innovation
    • Contact Us
  • Our Pipeline
    • Pipeline
    • Clinical Trials
  • Our Science
    • Scientific Approach
    • Scientific Publications
  • Investors
    • Investor Overview
    • Financials & Filings
    • Press Releases
    • SEC Filings
    • Investor Events
    • Corporate Governance
    • Stock Information
    • Contact IR
    • Historic Stock Lookup
    • Email Alerts
    • Analyst Coverage
  • Our Culture
    • Careers at Nektar
  • For Patients
  • linkedin
investor relations hero

Investor events

Upcoming Events

No upcoming events at this time.

Archived Events

Mar 12, 2026 5:00 PM EDT

Nektar Therapeutics Q4 2025 Financial Results

Click here for webcast
Mar 4, 2026 9:10 AM EST

TD Cowen 46th Annual Health Care Conference

Click here for webcast
Supporting Materials
TD Cowen 46th Annual Health Care Conference Presentation 3.1 MB
Feb 10, 2026 8:00 AM EST

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis

Click here for webcast
Supporting Materials
Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period 2.9 MB
Dec 16, 2025 8:00 AM EST

Nektar Therapeutics Analyst and Investor Event To Discuss REZOLVE-AA Topline Results

Click here for webcast
Supporting Materials
Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period 4.6 MB
Nov 20, 2025 11:00 AM GMT

Jefferies Global Healthcare Conference in London

Click here for webcast
Nov 6, 2025 5:00 PM EST

Nektar Therapeutics Q3 2025 Financial Results

Click here for webcast
Contact IR
Print Page
RSS
Email Alerts
Nektar Therapeutics
  • About Nektar
  • Our Pipeline
  • Our Science
  • Investors
  • Our Culture
  • For Patients
  • linkedin

©2026 Nektar Therapeutics

  • Privacy Policy
  • Terms of Use